Common Side Effects of Lurbinectedin
Lurbinectedin (Zepzelca), used for metastatic small cell lung cancer, often causes hematologic issues like neutropenia (low white blood cells), anemia, and thrombocytopenia (low platelets), plus fatigue, nausea, decreased appetite, musculoskeletal pain, diarrhea, and elevated liver enzymes.[1] Management focuses on monitoring, supportive care, and dose adjustments per prescribing guidelines.
Handling Blood Count Drops (Neutropenia, Anemia, Thrombocytopenia)
- Monitor complete blood counts weekly during the first two cycles, then every other cycle; more often if grade 3/4 toxicity occurs.[1]
- For grade 4 neutropenia or febrile neutropenia, hold treatment and resume at 25% dose reduction after recovery to grade ≤1.[1]
- Use growth factors like G-CSF (e.g., filgrastim) prophylactically if neutropenia recurs; transfuse platelets or red cells for severe drops.[1]
- Delay cycles until counts recover to avoid infections or bleeding risks.
Managing Nausea, Vomiting, and Diarrhea
- Administer antiemetics preemptively: dexamethasone 8-12 mg IV day before, day of, and day after infusion, plus 5-HT3 antagonists (ondansetron) and NK1 inhibitors (aprepitant) for breakthrough.[1]
- For diarrhea, start loperamide at first loose stool; escalate to octreotide if persistent.[1]
- Hydrate orally or IV; hold lurbinectedin for grade 3/4 events and resume at reduced dose after resolution.
Addressing Fatigue and Musculoskeletal Pain
- Advise rest, balanced nutrition, and light exercise like walking to combat fatigue.[1]
- Use acetaminophen or NSAIDs for pain; opioids for severe cases, but monitor for added bone marrow suppression.[1]
- Rule out anemia or electrolyte imbalances as contributors via labs.
Liver Enzyme Elevations and Other Issues
- Check liver function before each cycle; hold for grade 3/4 increases and resume at 25-50% reduction once ≤ grade 1.[1]
- For peripheral neuropathy (less common), use gabapentin or duloxetine; discontinue if grade 3/4.[1]
- Rhabdomyolysis (rare): monitor CPK, hydrate aggressively, and stop drug if confirmed.[1]
Dose Modifications and When to Hold or Reduce
| Severity (CTCAE Grade) | Action for Most Toxicities |
|-------------------------|----------------------------|
| Grade 1-2 | Continue, monitor closely |
| Grade 3 | Hold until ≤ grade 1, then resume (no reduction first time) |
| Grade 4 or recurrent grade 3 | Hold until ≤ grade 1, resume at 25% reduction; further issues trigger 50% cut or discontinuation[1] |
Maximum reductions cannot go below 1 mg flat dose (from 3.2 mg).[1] No dose adjustments needed for mild renal impairment.
Patient Tips and Monitoring Schedule
Patients should report fever >100.4°F, unusual bleeding, or persistent symptoms immediately to prevent hospitalization. Weekly bloodwork early on catches issues fast. Oncology teams often pair with nutritionists for appetite loss.[1]
[1]: Zepzelca (lurbinectedin) prescribing information, Jazz Pharmaceuticals, https://www.zepzelca.com/pdf/zepzelca-prescribing-information.pdf